Given the task definition, example input & output, solve the new input case.
Given a paragraph, generate a claim that is supported by the given paragraph. 1) The claim must contain information from within the paragraph. 2) A sentence within the paragraph can be used as a claim. 3) The claim should not have contradictions within the paragraph. 4) The claim should be at most one sentence long.
Example: "Although the story didn't cite the cost of appendectomy emergency or urgent surgery and we wish it had, we nonetheless will give it a satisfactory score because it at least cited what the editorial writer wrote, ""A secondary benefit is the savings to the hospital generated by minimizing staff and anesthesiologist presence late in the evening and during the wee hours of the morning."" As with our harms score above, although the story didn't give absolute numbers, in this case we think it was sufficient for it to report that ""The scientists found no significant difference among the groups in the patients' condition 30 days after surgery or in the length of their operation or hospital stay."" Although the story didn't give absolute numbers, in this case we think it was sufficient for it to report that ""The scientists found no significant difference among the groups in the patients' condition 30 days after surgery or in the length of their operation or hospital stay."" Despite running less than 300 words, this story did an adequate job in explaining the quality of the evidence, including pointing out limitations. No disease-mongering here. The story meets the bare minimum requirement for this criterion in that it at least cited what an editorial stated. The focus of the story was on a study comparing emergency appendectomy with surgery done up to 12 hours later or beyond. This is the whole focus of the story and one we applaud when it begins: ""Appendectomy is the most common emergency surgery in the world, but it doesn't have to be."" There were no claims made about the novelty of this research, and we may have wished for a bit more context on this. Nonetheless, the potential for guiding future care decisions was made clear. Not applicable. Given that the story only pulled excerpts from the journal article and the accompanying editorial, and didn't include any fresh quotes from interviews, we can't be sure of the extent to which it may have been influenced by a news release."
Output: Some appendicitis cases may not require 'emergency' surgery
The paragraph mentions that "Appendectomy is the most common emergency surgery in the world, but it doesn't have to be." which is considered evidence for the output. Thus, the output is a valid claim.

New input case for you: The Food and Drug Administration cleared a near-copy of the drug, dubbed Amjevita, developed by Amgen Inc. Regulators approved the drug for more than a half-dozen conditions listed on the original drug's label, including severe psoriasis and Crohn's diseases. Humira posted sales of nearly $15 billion in 2015 and was for many years the top-selling prescription drug in the world, according to data from IMS Health. It's the fourth time that the FDA has formally approved a so-called biosimilar, the industry term for a lower-cost version of a biotech drug. Biosimilar drugs, long available in Europe, are thought to have the potential to generate billions in savings for the U.S. health system. But currently only one biosimilar cleared by the FDA approval pathway is actually on the market in the U.S., Novartis' Zarxio, an alternative to Amgen's Neupogen that sells for about 15 percent less than the original product. The drug helps boost red blood cells in cancer patients. Amgen did not discuss plans for the drug's launch or price in a release issued Friday evening. But Wall Street analysts have noted that AbbVie claims it holds patents protecting Humira until at least 2022. They have previously estimated that Amgen's version could launch sometime between 2018 and 2022, depending on the outcome of court litigation. First approved in 2002, Humira accounted for 60 percent of AbbVie's total revenue last year. The injectable drug, which blocks chemicals linked to inflammation, is part of a family of biotech drugs including Enbrel and Remicade, which are also facing pending biosimilar competition. Development of lower-cost anti-inflammatory drugs is considered pivotal in reducing U.S. spending on specialty drugs, which has doubled to $150 billion since 2010, according to IMS Health. Thousand Oaks, California-based Amgen is itself a biotech powerhouse, and it too has medications facing competition from cheaper versions. The company is working to hedge those loses by developing lower-cost versions of competitors' drugs. AbbVie Inc. is based in North Chicago, Illinois.
Output:
FDA approves lower-cost alternative to biotech drug Humira.